Personalized Lab Tests
CELLSEARCH® Circulating Tumor Cell (CTC) Test
The CELLSEARCH® Circulating Tumor Cell (CTC) Test is the only FDA-cleared test that can capture and count CTC's for metastatic breast, prostate or colorectal cancer. CTC’s are an accurate predictor of progression free survival and overall survival, allowing for well-informed clinical decisions.
Health care providers can use the CELLSEARCH® Circulating Tumor Cell (CTC) Test to assess the success of a line of therapy much earlier and more frequently than what is typical with imaging (around 3 months and in some cases more). Changes in a patient’s prognosis can be readily identified when changes in the number of CTC’s are measured.
Earlier and more frequent information is invaluable to the physician, the patient and their families because:
targeted therapies can be much more costly,
detecting changes in a patient’s prognosis earlier may allow for a change in the treatment plan and
cancer patients may be able to avoid unnecessary side effects of therapies that are either not effective or that have become ineffective over the course of the treatment.